Mural Oncology’s (MURA) “Buy” Rating Reaffirmed at HC Wainwright

Mural Oncology (NASDAQ:MURA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 391.80% from the company’s previous close.

Mural Oncology Stock Performance

MURA stock opened at $3.66 on Wednesday. The firm has a fifty day moving average price of $3.85 and a 200 day moving average price of $3.58. Mural Oncology has a fifty-two week low of $2.87 and a fifty-two week high of $5.23. The firm has a market cap of $62.29 million, a PE ratio of -0.40 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period last year, the firm earned ($3.57) EPS. On average, equities analysts predict that Mural Oncology will post -7.54 EPS for the current year.

Institutional Investors Weigh In On Mural Oncology

Several institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC lifted its position in Mural Oncology by 1.4% in the fourth quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock worth $565,000 after buying an additional 2,470 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Mural Oncology by 2.6% in the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after acquiring an additional 4,731 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Mural Oncology by 12.0% in the 4th quarter. Two Sigma Investments LP now owns 65,150 shares of the company’s stock worth $210,000 after acquiring an additional 6,993 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Mural Oncology by 22.0% in the 4th quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after acquiring an additional 7,197 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after purchasing an additional 11,423 shares during the period. 80.21% of the stock is owned by institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.